jueves, 12 de enero de 2017
USA: Sanofi, Lilly & Novo "pricing collusion"
The implicated firms have strongly denied the claims, stating that their actions have been perfectly legal and that the price rises are nothing more than representative of a highly competitive market and reimbursement plans which put “an unfair burden on people with diabetes.”
Ver
Etiquetas:
Comunicación,
Lilly,
Marketing,
Precio,
SanofiAventis
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario